View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 4, 2011

AstraZeneca unit acquires tremelimumab rights from Pfizer

AstraZeneca's MedImmune subsidiary has reached an agreement with US-based pharmaceutical major Pfizer for the potential cancer treatment tremelimumab.

By Liam Stoker

AstraZeneca ‘s MedImmune subsidiary has reached an agreement with US-based pharmaceutical major Pfizer for the potential cancer treatment tremelimumab.

MedImmune will assume global development rights to the CTLA-4 monoclonal antibody, whereas Pfizer will retain the rights to use the drug alongside combination therapies.

MedImmune Research and Development head Bahija Jallal said: "Adding another immunotherapeutic approach to our oncology pipeline… exemplifies our continued commitment to embracing this new era of cancer."

Tremelimumab has had something of a chequered past, with Pfizer discontinuing a late-stage trial of the drug in 2008 following a review of interim data that showed the drug would not out-perform standard chemotherapy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology